MCM
ACAD icon

Manchester Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Manchester Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,031
Closed -$50K – 1023
2021
Q2 		$50K Hold
2,031
– – 0.01% 384
2021
Q1 		$52K Sell
2,031
-6
-0.3% -$264 0.01% 378
2020
Q4 		$109K Hold
2,037
– – 0.02% 304
2020
Q3 		$84K Buy
+2,037
New +$88K 0.01% 299

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Manchester Capital Management's ACAD Position: Q3 2021 in Review

Manchester Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 2,031 shares — an estimated $50K sold.

Manchester Capital Management first reported a position in ACAD in Q3 2020 and held it in 4 quarters. The position peaked at $109K in Q4 2020. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

  • Manchester Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Manchester Capital Management sold 2,031 Acadia Pharmaceuticals shares in Q3 2021, an estimated $50K.
  • Manchester Capital Management first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Manchester Capital Management's Acadia Pharmaceuticals position peaked at $109K in Q4 2020.
  • 237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on Manchester Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.